Say Goodbye To NASH And Hello To MASH

The revised nomenclature of metabolic dysfunction-associated steatohepatitis (MASH), rather than non-alcoholic steatohepatitis (NASH), appears to be taking hold among stakeholders in the liver disease space.

Name change
The biopharma industry gradually is adapting to the name change from NASH to MASH • Source: Shutterstock

The shift in terminology from NASH to MASH seems to be taking hold judging by public statements from companies working in the space, as well as some of the market analysts commenting on developments in metabolic dysfunction-associated steatohepatitis, the disease formerly known as non-alcoholic steatohepatitis.

The nomenclature change is intended to de-stigmatize the disease by eliminating references to alcohol use and fatty liver and also clarify what degree of alcohol consumption falls outside the definition...

Key Takeaways
  • Stakeholders groups are encouraging the use of a new acronym – MASH – to replace the existing NASH in an effort destigmatize the disease.

  • ...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By 

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

More from Business

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.